Trials / Completed
CompletedNCT01690533
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 497 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg (hereinafter as "Avelox") in treating secondary infection of chronic respiratory disease.It is a local prospective and observational study of patients who have received Avelox tablets for Laryngopharyngitis, Tonsillitis, Bronchitis acute, Pneumonia, Secondary infection in chronic respiratory diseases, Sinusitis. A total of 500 patients are to be enrolled and assessed during the period of treatment with Avelox.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelox (Moxifloxacin, BAY12-8039) | Patients treated with Moxifloxacin in daily clinical practice |
Timeline
- Start date
- 2008-05-13
- Primary completion
- 2010-12-14
- Completion
- 2013-07-19
- First posted
- 2012-09-21
- Last updated
- 2018-05-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01690533. Inclusion in this directory is not an endorsement.